CAMBRIDGE, Mass., March 22, 2018 /3BL Media/ – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the release of the Company’s 2017 Annual Responsibility Review. The Review, available at shire.com/responsibility outlines Shire’s new Responsibility strategy that includes ambitious long-term goals to be achieved by 2025, aimed at further enhancing the Company’s commitment to Responsibility and positively impacting patients, our employees, and our communities.
In February of 2016, we committed $3 million over three years to SeriousFun Children’s Network. Our support will enable nearly 1,000 children, many with rare diseases, to attend SeriousFun’s transformative camps and programs free of charge. This is a look at our partnership in year two!
Our volunteers had this to say (and more) in the video above:
"What I experienced at camp was beyond my expectations."
"Every camper was made to feel that FUN was the most important goal (of the day)."
"The campers attitudes and strength were absolutely contagious."
Shire is the global leader in serving patients with rare diseases. We strive to develop innovative therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.
Shire employees across the globe celebrated Pride Month in June through a variety of events ranging from city-wide parades to local panel events. Activities were led by B-Equal, Shire’s Business Resource Group (BRG) that supports the inclusion of Lesbian, Gay, Bisexual and Transgender Professionals (LGBT+) and their Allies. Hundreds of colleagues, along with their family and friends, joined together to show their support of the LGBT+ community and recognize the importance of being an inclusive workplace.
Did you know of 7,000 rare diseases, only 5% have treatments available?
On July 18th, Shire invited professionals local to Cambridge, MA to participate in Rare in Kendall Square: Collaborating to Advance Innovation in Rare Disease. Over 200 attendees gathered to network and weigh in on a panel discussion centered around the idea that partnerships can advance treatment options.
“Our fight against rare diseases cannot be waged alone – unique partnership models are critical,” said Flemming Ornskov, M.D., M.P.H. and CEO of Shire.